Medrano-Guzmán R, Alvarado-Cabrero I, González-Rodríguez D, López-García SC, Páez-Agraz F

Language: Spanish
References: 10
Page: 243-248
PDF size: 67.04 Kb.

ABSTRACT

Objective: to determine surgical prognostic variables from a retrospective cohort of histopathologically confirmed gastroenteropancreatic neuroendocrine tumors (GEP-NET) in Mexican subjects.
Methods: consecutive patients treated for GEP-NET from 1999 through 2007 at Oncological Hospital were included. Demographic, clinical variables, disease-free survival were retrieved.
Results: forty-eight patients were included, 29 (60.4 %) female with a mean age of 54 years. Overall survival time was 43.7 months and disease-free survival was 33 months. Negative statistically significant overall survival time predictors were 2 and 3 histological types (HR 5.5. CI 2.0-21, p = 0.0001), tumor size › 2 cm (HR 8.8, CI 1 .29-75, p = 0.002), the presence of metastasis (HR 2.4, CI 1.2-9.6, p = 0.0001) and tumor resectability (HR 9.8, CI 2.9-40.2, p = 0.0001). For the disease-free period, only the histological type (2 or 3) was a negative outcome variable.
Conclusions: histological type, tumor size, the presence of metastasis, and tumor non resectability were significant survival predictors.

REFERENCES

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker UV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9(1):61-72.

2. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol 2001;22(4):309-339.

3. Lee CS, Kaestner KH. Clinical endocrinology and metabolism. Development of gut endocrine cells. Best Pract Res Clin Endocrinol Metab 2004;18(4):453-462.

4. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. Second edition. New York: Springer; 2000.

5. Klöppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 2010;456(6): 595-597.

6. Öberg K, Akerström G, Rindi G, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 (Suppl 5): v223-227.

7. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. On behalf of UKNETwork for neuroendocrine tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl 4):iv1-iv16. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867801/pdf/v054p00iv1.pdf

8. ENETS Consensus Guidelines for the Standard of Care for Patients with Digestive Neuroendocrine Tumors. Disponible en http://www.neuroendocrine.net/guidelines_tnm_classifications.html&OPEN=menue,14

9. Portela-Gomes GM, Hacker GW, Weitgasser R. Neuroendocrine cell markers for pancreatic islets and tumors. Appl Immunohistochem Mol Morphol 2004;12(3):183-192.

10. Medrano-Guzmán R, Ochoa-Carrillo FJ, Alvarado-Cabrero I, Barreto-Zúñiga R, Brom-Valladares RC, Cravioto-Villanueva A, et al. Guías de diagnóstico y tratamiento de tumores neuroendocrinos gastroenteropancreáticos. Patologia 2009;47(3):220-228.